JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

MDT

93.37

-0.77%↓

VEEV

292.12

-1.14%↓

A

145.91

-0.57%↓

Search

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

17.75 0.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.45

Max

17.86

Pagrindiniai rodikliai

By Trading Economics

Pajamos

110M

64M

Pardavimai

12M

100M

P/E

Sektoriaus vid.

30.193

37.461

Pelno marža

63.508

Darbuotojai

127

EBITDA

111M

84M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+114.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-82M

1.1B

Ankstesnė atidarymo kaina

17.52

Ankstesnė uždarymo kaina

17.75

Naujienos nuotaikos

By Acuity

34%

66%

97 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-28 23:50; UTC

Karštos akcijos

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

2025-10-28 23:25; UTC

Uždarbis

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

2025-10-28 23:18; UTC

Uždarbis

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

2025-10-28 22:20; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

2025-10-28 22:13; UTC

Uždarbis

Wal-Mart de Mexico Net Profit Falls in 3Q

2025-10-28 21:38; UTC

Uždarbis

Correction to Visa Sales Jump Article

2025-10-28 21:17; UTC

Uždarbis

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

2025-10-28 21:07; UTC

Uždarbis

Visa Sales Jump as Consumers Keep Spending -- Update

2025-10-28 21:02; UTC

Uždarbis

Mondelez Tempers Outlook as Costs Rise

2025-10-28 23:51; UTC

Rinkos pokalbiai

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

2025-10-28 23:42; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

2025-10-28 23:02; UTC

Uždarbis

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

2025-10-28 23:01; UTC

Uždarbis

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

2025-10-28 22:46; UTC

Uždarbis

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

2025-10-28 22:45; UTC

Uždarbis

SK Hynix 3Q Net KRW12.6T >000660.SE

2025-10-28 22:44; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.44T >000660.SE

2025-10-28 22:43; UTC

Uždarbis

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

2025-10-28 22:42; UTC

Uždarbis

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

2025-10-28 22:40; UTC

Uždarbis

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

2025-10-28 22:22; UTC

Uždarbis

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

2025-10-28 22:20; UTC

Uždarbis

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

2025-10-28 22:02; UTC

Uždarbis

Review & Preview: Earnings Extravaganza -- Barrons.com

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-28 21:42; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

2025-10-28 21:20; UTC

Uždarbis

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

2025-10-28 21:19; UTC

Uždarbis

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

2025-10-28 21:18; UTC

Uždarbis

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

114.45% į viršų

12 mėnesių prognozė

Vidutinis 38 USD  114.45%

Aukščiausias 55 USD

Žemiausias 17 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

3

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.57 / 18.75Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

97 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat